ProQR Reports Q3 2025 Financial Results Amid Revenue Decline
I'm PortAI, I can summarize articles.
ProQR Therapeutics N.V. reported its Q3 2025 financial results, revealing a revenue decline to €2,882,000 for the quarter and €11,218,000 for the nine-month period. Operating costs rose, resulting in an operating loss of €11,284,000 for the quarter. The biotechnology sector's challenges are impacting ProQR's performance, necessitating strategic adjustments. Analysts rate PRQR stock as a Hold with a $2.50 price target, while TipRanks' AI Analyst suggests a Neutral outlook due to significant financial challenges and a negative P/E ratio. ProQR focuses on RNA therapies for genetic eye diseases and has a market cap of $250.4M.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments